Diabetes Care:低碳水化合物治疗对妊娠糖尿病无效

2013-05-27 Diabetes Care dxy

基于碳水化合物(CHO)分布和数量控制的医学营养治疗是妊娠糖尿病(GDM)的初始治疗,但是,需要随机对照试验对不同的饮食策略进行比较。为了探讨GDM治疗中的低CHO饮食与正常饮食相比,是否可以导致相似的妊娠结局下更低的胰岛素治疗使用率,来自西班牙莱里达大学医院内分泌与营养科的Didac Mauricio教授及其团队进行了一项研究,该研究结果在线发表在2013年4月5日的《糖尿病治疗》(Diabet

基于碳水化合物(CHO)分布和数量控制的医学营养治疗是妊娠糖尿病(GDM)的初始治疗,但是,需要随机对照试验对不同的饮食策略进行比较。为了探讨GDM治疗中的低CHO饮食与正常饮食相比,是否可以导致相似的妊娠结局下更低的胰岛素治疗使用率,来自西班牙莱里达大学医院内分泌与营养科的Didac Mauricio教授及其团队进行了一项研究,该研究结果在线发表在2013年4月5日的《糖尿病治疗》(Diabetes Care)杂志上。该研究发现GDM的治疗中使用低CHO饮食不能减少需要使用胰岛素治疗的患者数量,并产生相似的妊娠结局。在GDM,CHO量(总热量的40 vs 55%)不影响胰岛素的需求或妊娠结局。

该研究是一项开放的、随机对照试验,共包括152例GDM女性,并被分配到接受低CHO含量的饮食(CHO占总膳食能量的40%)或对照饮食(CHO占总膳食能量的55%)。通过3日饮食记录法对CHO摄入进行评估。并且评估主要的妊娠结局。

该研究结果表明,两个治疗组之间,需要使用胰岛素女性的比例没有明显差异(低CHO 54.7% vs 对照组54.7%;P=1)。饮食记录确认两组间CHO消耗量由差异(P=0.0001)。两个治疗组之间产科和围产期结局没有发现差异。

该研究发现,GDM的治疗中使用低CHO饮食不能减少需要使用胰岛素治疗的患者数量,并产生相似的妊娠结局。在GDM,CHO量(总热量的40 vs 55%)不影响胰岛素的需求或妊娠结局。

Low-Carbohydrate Diet for the Treatment of Gestational Diabetes: A randomized controlled trial.
OBJECTIVE
Medical nutrition therapy based on the control of the amount and distribution of carbohydrates (CHO) is the initial treatment for gestational diabetes mellitus (GDM), but there is a need for randomized controlled trials comparing different dietary strategies. The purpose of this study was to test the hypothesis that a low-CHO diet for the treatment of GDM would lead to a lower rate of insulin treatment with similar pregnancy outcomes compared with a control diet.
RESEARCH DESIGN AND METHODS
A total of 152 women with GDM were included in this open, randomized controlled trial and assigned to follow either a diet with low-CHO content (40% of the total diet energy content as CHO) or a control diet (55% of the total diet energy content as CHO). CHO intake was assessed by 3-day food records. The main pregnancy outcomes were also assessed.
RESULTS
The rate of women requiring insulin was not significantly different between the treatment groups (low CHO 54.7% vs. control 54.7%; P = 1). Daily food records confirmed a difference in the amount of CHO consumed between the groups (P = 0.0001). No differences were found in the obstetric and perinatal outcomes between the treatment groups.
CONCLUSIONS
Treatment of women with GDM using a low-CHO diet did not reduce the number of women needing insulin and produced similar pregnancy outcomes. In GDM, CHO amount (40 vs. 55% of calories) did not influence insulin need or pregnancy outcomes.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1636678, encodeId=0c0716366e87c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Mar 05 05:16:00 CST 2014, time=2014-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901096, encodeId=acb6190109693, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Apr 14 09:16:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906274, encodeId=a4e019062e465, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Wed Dec 11 10:16:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345117, encodeId=6b83134511eb6, content=<a href='/topic/show?id=c2462629612' target=_blank style='color:#2F92EE;'>#低碳水化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26296, encryptionId=c2462629612, topicName=低碳水化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed May 29 09:16:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464339, encodeId=000314643398e, content=<a href='/topic/show?id=9b04641580e' target=_blank style='color:#2F92EE;'>#水化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64158, encryptionId=9b04641580e, topicName=水化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1276671681, createdName=yuanming9, createdTime=Wed May 29 09:16:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759291, encodeId=c41f1e59291bc, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 15 15:16:00 CST 2013, time=2013-07-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1636678, encodeId=0c0716366e87c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Mar 05 05:16:00 CST 2014, time=2014-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901096, encodeId=acb6190109693, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Apr 14 09:16:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906274, encodeId=a4e019062e465, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Wed Dec 11 10:16:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345117, encodeId=6b83134511eb6, content=<a href='/topic/show?id=c2462629612' target=_blank style='color:#2F92EE;'>#低碳水化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26296, encryptionId=c2462629612, topicName=低碳水化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed May 29 09:16:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464339, encodeId=000314643398e, content=<a href='/topic/show?id=9b04641580e' target=_blank style='color:#2F92EE;'>#水化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64158, encryptionId=9b04641580e, topicName=水化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1276671681, createdName=yuanming9, createdTime=Wed May 29 09:16:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759291, encodeId=c41f1e59291bc, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 15 15:16:00 CST 2013, time=2013-07-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1636678, encodeId=0c0716366e87c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Mar 05 05:16:00 CST 2014, time=2014-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901096, encodeId=acb6190109693, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Apr 14 09:16:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906274, encodeId=a4e019062e465, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Wed Dec 11 10:16:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345117, encodeId=6b83134511eb6, content=<a href='/topic/show?id=c2462629612' target=_blank style='color:#2F92EE;'>#低碳水化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26296, encryptionId=c2462629612, topicName=低碳水化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed May 29 09:16:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464339, encodeId=000314643398e, content=<a href='/topic/show?id=9b04641580e' target=_blank style='color:#2F92EE;'>#水化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64158, encryptionId=9b04641580e, topicName=水化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1276671681, createdName=yuanming9, createdTime=Wed May 29 09:16:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759291, encodeId=c41f1e59291bc, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 15 15:16:00 CST 2013, time=2013-07-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1636678, encodeId=0c0716366e87c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Mar 05 05:16:00 CST 2014, time=2014-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901096, encodeId=acb6190109693, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Apr 14 09:16:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906274, encodeId=a4e019062e465, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Wed Dec 11 10:16:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345117, encodeId=6b83134511eb6, content=<a href='/topic/show?id=c2462629612' target=_blank style='color:#2F92EE;'>#低碳水化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26296, encryptionId=c2462629612, topicName=低碳水化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed May 29 09:16:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464339, encodeId=000314643398e, content=<a href='/topic/show?id=9b04641580e' target=_blank style='color:#2F92EE;'>#水化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64158, encryptionId=9b04641580e, topicName=水化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1276671681, createdName=yuanming9, createdTime=Wed May 29 09:16:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759291, encodeId=c41f1e59291bc, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 15 15:16:00 CST 2013, time=2013-07-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1636678, encodeId=0c0716366e87c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Mar 05 05:16:00 CST 2014, time=2014-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901096, encodeId=acb6190109693, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Apr 14 09:16:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906274, encodeId=a4e019062e465, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Wed Dec 11 10:16:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345117, encodeId=6b83134511eb6, content=<a href='/topic/show?id=c2462629612' target=_blank style='color:#2F92EE;'>#低碳水化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26296, encryptionId=c2462629612, topicName=低碳水化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed May 29 09:16:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464339, encodeId=000314643398e, content=<a href='/topic/show?id=9b04641580e' target=_blank style='color:#2F92EE;'>#水化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64158, encryptionId=9b04641580e, topicName=水化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1276671681, createdName=yuanming9, createdTime=Wed May 29 09:16:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759291, encodeId=c41f1e59291bc, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 15 15:16:00 CST 2013, time=2013-07-15, status=1, ipAttribution=)]
    2013-05-29 yuanming9
  6. [GetPortalCommentsPageByObjectIdResponse(id=1636678, encodeId=0c0716366e87c, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Mar 05 05:16:00 CST 2014, time=2014-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901096, encodeId=acb6190109693, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Apr 14 09:16:00 CST 2014, time=2014-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906274, encodeId=a4e019062e465, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Wed Dec 11 10:16:00 CST 2013, time=2013-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345117, encodeId=6b83134511eb6, content=<a href='/topic/show?id=c2462629612' target=_blank style='color:#2F92EE;'>#低碳水化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26296, encryptionId=c2462629612, topicName=低碳水化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed May 29 09:16:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464339, encodeId=000314643398e, content=<a href='/topic/show?id=9b04641580e' target=_blank style='color:#2F92EE;'>#水化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64158, encryptionId=9b04641580e, topicName=水化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1276671681, createdName=yuanming9, createdTime=Wed May 29 09:16:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759291, encodeId=c41f1e59291bc, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 15 15:16:00 CST 2013, time=2013-07-15, status=1, ipAttribution=)]

相关资讯

AMA:美国医学会公布心血管疾病和糖尿病预防任务

  4月22日,美国医学会(AMA)公布“改善健康结局倡议”第一期任务,即控制心血管疾病和2型糖尿病危险因素,主要目标是促使血压、血糖和血脂水平达标。   AMA指出,美国1/3死因为心血管疾病,超过1/3的成年人患糖尿病或处于糖尿病前期。这两大类疾病每年需消耗5000亿美元以上。因此,AMA发起“改善健康结局倡议”,联合政府、医生和患者来预防和控制心血管疾病和糖尿病,促使所有成年人的血压、血糖

DDW 2013:二甲双胍或降低糖尿病患者结直肠癌风险

  奥兰多——在消化疾病周(DDW)上发表的一项Meta分析显示,二甲双胍可能与2型糖尿病患者的结直肠癌(CRC)风险降低有关。   罗切斯特梅奥医院的Siddharth Singh医生报告称,磺酰脲类和胰岛素均与CRC风险降低无关,反而显示出风险增加的不显著趋势。未观察到CRC与噻唑烷二酮(TZD)类药物之间有关。   糖尿病是明确的CRC危险因素,而且临床前和观察性研究已显示,抗糖尿病药物

Hypertension:合并隐匿性高血压的糖尿病患者需进一步降压治疗

尽管大家对糖尿病患者隐匿性高血压(masked hypertension)的特点已经很清楚。然而对于这些患者临床上进行降压治疗的意义尚未完全清楚。IDACO研究(The current International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes )中的受试

空气污染或诱发糖尿病

德国研究人员发现,城市交通引起的空气污染可能令儿童产生胰岛素抵抗的风险增加,致使成年后容易罹患糖尿病。   德国环境卫生研究中心的这项研究涉及397名10岁儿童。研究人员采集他们的血样,检测血糖和胰岛素水平,同时收集有关他们居住地空气污染程度的数据。   综合考虑研究对象的出生时体重、身高体重指数(BMI)和暴露在二手烟环境中的情况,研究人员发现,空气中二氧化氮和汽车尾

DDW 2013:自行无针针灸治疗控制糖尿病胃轻瘫患者消化不良有效

  在5月18日至5月21日召开的美国消化疾病周上,来自美国田纳西技术大学医学部的研究人员Sarosiek发表题为《自行无针针灸治疗控制糖尿病胃轻瘫患者的消化不良与胃食管反流症状》的论文。针灸是通过刺激皮肤内的针灸穴位治疗患者的一种替代医学方法。临床适应证包括控制疼痛及消化不良症状。对照研究的缺乏是文献中结果不一致的主要原因。检验采用定制的无线微刺激器进行无针经皮电神经刺激(TEA)的新方法,评价

武田制药糖尿病药物Fasiglifam后期临床试验效果显著

5月20日,武田制药发布了旗下一款糖尿病新药Fasiglifam的积极后期临床试验数据。在熊本举行的日本糖尿病学会会议上,武田制药宣布了该药物的一项III期临床试验的数据,数据显示日服一次25mg和50mg剂量的Fasiglifam表现出明显的统计学意义,2型糖尿病患者临床相关的糖化血红蛋白水平降低。武田制药表示Fasiglifam是首个进入后期开发阶段的GPR40激动剂。 在192名患者参与的